• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JCI Insight . A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies

tetano

Editor, Senior Moderator
JCI Insight


. 2024 Mar 8;9(5):e155789.
doi: 10.1172/jci.insight.155789. A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies

Juan Shi[SUP] 1 [/SUP], Jian Zheng[SUP] 2 [/SUP], Xiujuan Zhang[SUP] 3 [/SUP], Wanbo Tai[SUP] 3 [/SUP], Ryan Compas[SUP] 4 [/SUP], Jack Deno[SUP] 4 [/SUP], Natalie Jachym[SUP] 4 [/SUP], Abhishek K Verma[SUP] 2 [/SUP], Gang Wang[SUP] 1 [/SUP], Xiaoqing Guan[SUP] 1 [/SUP], Abby E Odle[SUP] 2 [/SUP], Yushun Wan[SUP] 5 [/SUP], Fang Li[SUP] 5 6 [/SUP], Stanley Perlman[SUP] 2 [/SUP], Liang Qiao[SUP] 4 [/SUP], Lanying Du[SUP] 1 [/SUP]



Affiliations
Free article Abstract

SARS-CoV-2 spike-based vaccines are used to control the COVID-19 pandemic. However, emerging variants have become resistant to antibody neutralization and further mutations may lead to full resistance. We tested whether T cells alone could provide protection without antibodies. We designed a T cell-based vaccine in which SARS-CoV-2 spike sequences were rearranged and attached to ubiquitin. Immunization of mice with the vaccine induced no specific antibodies, but strong specific T cell responses. We challenged mice with SARS-CoV-2 wild-type strain or an Omicron variant after the immunization and monitored survival or viral titers in the lungs. The mice were significantly protected against death and weight loss caused by the SARS-CoV-2 wild-type strain, and the viral titers in the lungs of mice challenged with the SARS-CoV-2 wild-type strain or the Omicron variant were significantly reduced. Importantly, depletion of CD4+ or CD8+ T cells led to significant loss of the protection. Our analyses of spike protein sequences of the variants indicated that fewer than one-third presented by dominant HLA alleles were mutated and that most of the mutated epitopes were in the subunit 1 region. As the subunit 2 region is conservative, the vaccines targeting spike protein are expected to protect against future variants due to the T cell responses.

Keywords: Adaptive immunity; COVID-19; T cells; Vaccines.

 
Back
Top Bottom